This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00372931
First received: September 6, 2006
Last updated: April 21, 2008
Last verified: April 2008
September 6, 2006
April 21, 2008
May 2006
August 2007   (Final data collection date for primary outcome measure)
Mean IOP change from baseline
Same as current
Complete list of historical versions of study NCT00372931 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine whether AL-37807 is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Open-Angle Glaucoma
  • Ocular Hypertension
Drug: AL-37807
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
Not Provided
August 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients of either sex and any race with open-angle glaucoma or ocular hypertension; logMAR visual acuity not worse than 0.60; additionally clinically relevant ophthalmic or systemic conditions may be excluded

Exclusion Criteria:

  • Under 18
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00372931
C-06-15
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Alcon Research
Not Provided
Study Director: Theresa Landry Study Director
Alcon Research
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP